Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Keyword(s):
2016 ◽
Vol 18
(8)
◽
pp. 803-811
◽
Keyword(s):
2019 ◽
Vol 21
(4)
◽
pp. 837-843
◽
Keyword(s):
2018 ◽
Vol 20
(12)
◽
pp. 2876-2884
◽
Keyword(s):